Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | EDNRA | P25101 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | FBP1 | P09467 | 11/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | EDNRB | P24530 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30642945 | 0.94 | KMT2A (0.62) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL1087618 | 0.85 | KMT2A (0.67) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL29547938 | 0.85 | KMT2A (0.67) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL19246050 | 0.84 | KMT2A (0.56) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL8224043 | 0.83 | KMT2A (0.65) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL22446712 | 0.83 | KMT2A (0.65) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL418539 | 0.83 | KMT2A (0.65) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL27784622 | 0.83 | KMT2A (0.65) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL12520277 | 0.83 | KMT2A (0.65) | KMT2AMEN1EDNRAALDH1A1FBP1 | |
| SCHEMBL9090583 | 0.80 | FBP1 (0.65) | KMT2AALDH1A1FBP1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11187980-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210302838-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20200241414-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200192222-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-20200073237-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | KMT2A 4700/4885MEN1 91/4885EDNRA 2270/4885 |
| US-20200241414-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | INSR, HNRNPU, HNRNPR | KMT2A 1882/4885MEN1 2251/4885EDNRA 756/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | KMT2A 2992/4885MEN1 2168/4885EDNRA 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.